Ameriprise
KYMR icon

Ameriprise’s Kymera Therapeutics KYMR Stock Holding History

Ameriprise’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Sell
3,358
-68
-2% -$5.38K ﹤0.01% 3779
2025
Q4 		$267K Sell
3,426
-20,632
-86% -$1.39M ﹤0.01% 3842
2025
Q3 		$1.36M Buy
24,058
+4,525
+23% +$204K ﹤0.01% 3205
2025
Q2 		$852K Buy
19,533
+4,159
+27% +$143K ﹤0.01% 3333
2025
Q1 		$421K Buy
15,374
+6,830
+80% +$249K ﹤0.01% 3557
2024
Q4 		$344K Buy
+8,544
New +$386K ﹤0.01% 3668
2023
Q2 		– Sell
-7,470
Closed -$221K – 3960
2023
Q1 		$221K Buy
+7,470
New +$241K ﹤0.01% 3700

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ameriprise's KYMR Position: Q1 2026 in Review

Ameriprise reduced its Kymera Therapeutics (KYMR) stake by 2% in Q1 2026, selling an estimated $5.38K and leaving 3,358 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #3779.

Ameriprise first reported a position in KYMR in Q1 2023 and has held it in 7 quarters since. The position peaked at $1.36M in Q3 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Ameriprise held 3,358 shares of Kymera Therapeutics worth $280K as of Q1 2026.
  • Ameriprise sold 68 Kymera Therapeutics shares in Q1 2026, an estimated $5.38K.
  • Kymera Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3779 holding.
  • Ameriprise first reported a position in Kymera Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • Ameriprise's Kymera Therapeutics position peaked at $1.36M in Q3 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.